News & Updates

Show Multimedia Only
Low-dose polypill: Another step forward in hypertension management?

Low-dose polypill: Another step forward in hypertension management?

12 Dec 2022 byRoshini Claire Anthony

A polypill comprising ultra-low doses of four antihypertensive drugs shows promise in reducing blood pressure (BP) levels compared with standard monotherapy, according to a small study presented at AHA 2022.

Low-dose polypill: Another step forward in hypertension management?

12 Dec 2022
Asians with MET exon 14 skipping NSCLC achieve durable response with tepotinib

Asians with MET exon 14 skipping NSCLC achieve durable response with tepotinib

12 Dec 2022
CV benefits of dapagliflozin evident regardless of baseline kidney function

CV benefits of dapagliflozin evident regardless of baseline kidney function

11 Dec 2022 byRoshini Claire Anthony

The cardiovascular (CV) benefit of dapagliflozin in patients with heart failure with mildly reduced or preserved ejection fraction (HFmrEF/HFpEF) is evident regardless of baseline kidney function, according to an analysis of the DELIVER* trial presented at Kidney Week 2022.

CV benefits of dapagliflozin evident regardless of baseline kidney function

11 Dec 2022
Edaravone confers neuroprotection in stroke patients

Edaravone confers neuroprotection in stroke patients

10 Dec 2022

Edaravone appears to be safe and effective in the treatment of patients with ischaemic stroke, yielding improvements in activities of daily living and neurologic deficits in the short term, a study has found.

Edaravone confers neuroprotection in stroke patients

10 Dec 2022